Pulmonx financials
$1.98+1.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $90.5M | $83.8M | $68.7M | $53.7M | $48.4M | $32.7M |
| Gross profit | $67.1M | $62.0M | $50.8M | $39.9M | $35.6M | $21.2M |
| Gross margin | 74.2% | 74.0% | 73.9% | 74.3% | 73.6% | 64.8% |
| Operating income | -$53.7M | -$57.7M | -$61.9M | -$58.6M | -$47.3M | -$32.3M |
| Net income | -$54.0M | -$56.4M | -$60.8M | -$58.9M | -$48.7M | -$32.2M |
| Net margin | −59.7% | −67.3% | −88.6% | −109.8% | −100.5% | −98.5% |
| Diluted EPS | $-1.33 | $-1.44 | $-1.60 | $-1.59 | $-1.35 | $-3.16 |
| EBITDA | -$52.6M | -$56.2M | -$60.4M | -$54.6M | -$46.4M | -$31.8M |
| Operating cash flow | -$32.4M | -$31.5M | -$37.6M | -$45.1M | -$41.4M | -$30.6M |
| Free cash flow | -$32.8M | -$33.0M | -$38.4M | -$46.4M | -$45.1M | -$31.5M |
| Diluted shares | 40.7M | 39.1M | 38.0M | 37.1M | 36.1M | 10.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $69.8M | $70.9M | $83.5M | $101.7M | $148.5M | $231.6M |
| Short-term investments | $0.00 | $30.6M | $33.6M | $39.4M | $31.6M | $0.00 |
| Total debt | $37.1M | $37.2M | $37.2M | $17.3M | $17.6M | $17.4M |
| Total assets | $129.3M | $162.8M | $177.8M | $193.7M | $235.2M | $263.7M |
| Total liabilities | $75.2M | $77.0M | $59.5M | $39.7M | $41.9M | $37.6M |
| Shareholders' equity | $54.1M | $85.8M | $118.3M | $154.0M | $193.2M | $226.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology